Warning Letters Special Report: The Decline And Fall Of Morton Grove Pharmaceuticals

It was bad enough that out-of-specification investigations were hugely inadequate, but the firm’s response to the FDA’s findings was even worse.

2022 Warning Letters Special Report
how morton grove wound up with a consent decree • Source: Shutterstock

US Food and Drug Administration warning letters are not always enough to compel improvements, and legal action may eventually follow, like it did for a manufacturing facility in Illinois that became a talking point for FDA compliance officials at recent conferences.

The denouement for the facility, and the string of FDA compliance actions and sometimes baffling company failure to respond, was...

More from Manufacturing

More from Compliance